Modular Medical Announces First Human Use of MODD1 Pump to Deliver Insulin.
ByAinvest
Wednesday, Aug 6, 2025 8:12 am ET1min read
MODD--
The MODD1 pump, designed specifically to target the estimated $3 billion adult "almost-pumpers" market, has been cleared by the U.S. Food and Drug Administration (FDA) for human use. The pump is currently delivering insulin to a clinician with Type 1 diabetes under FDA institutional review board approval. The company plans to expand testing to multiple clinicians across multiple sites in mid-August 2025 [2].
The MODD1 pump's controller module is identical to that of Modular Medical's tubeless Pivot model, demonstrating the company's strategy of leveraging shared technology across multiple product lines. This approach not only accelerates development timelines but also reduces costs [2].
Jeb Besser, CEO of Modular Medical, commented, "This is another step in the maturation of the Modular Medical patch pump delivery platform. The pump controller module for MODD1 and the tubeless Pivot are identical, and the successful delivery of insulin has been a milestone we have anticipated since we began development."
Modular Medical's focus on a user-friendly and affordable design aims to address the limitations of current insulin delivery systems that have prevented wider adoption among patients who could benefit from pump therapy [2].
The company's successful human testing phase represents one of the final steps before potential commercial deployment, though regulatory requirements for expanded use will need to be satisfied before full market release. This methodical approach—starting with a single clinician before expanding—aligns with best practices in medical device development by allowing for controlled assessment before broader deployment [2].
References
[1] https://www.newswire.com/news/modular-medical-announces-modd1-cartridge-line-validated-for-human-use
[2] https://www.stocktitan.net/news/MODD/modular-medical-announces-first-human-use-of-modd1-pump-delivering-y9zn4o8av6vc.html
Modular Medical has announced the first human use of its MODD1 pump to deliver insulin to a person with Type 1 diabetes. The pump has been cleared by the FDA and is intended for the adult "almost-pumpers" market. The company plans to deploy the pump on multiple clinicians in mid-August. The MODD1 is designed to target the estimated $3 billion adult market with its user-friendly and affordable design.
San Diego, CA — Modular Medical, Inc. (Nasdaq: MODD), a leading insulin delivery technology company, has announced a significant milestone in its commercialization journey. The company has successfully conducted the first human use of its MODD1 insulin pump to deliver insulin to a person with Type 1 diabetes, marking a crucial step towards broader market deployment [2].The MODD1 pump, designed specifically to target the estimated $3 billion adult "almost-pumpers" market, has been cleared by the U.S. Food and Drug Administration (FDA) for human use. The pump is currently delivering insulin to a clinician with Type 1 diabetes under FDA institutional review board approval. The company plans to expand testing to multiple clinicians across multiple sites in mid-August 2025 [2].
The MODD1 pump's controller module is identical to that of Modular Medical's tubeless Pivot model, demonstrating the company's strategy of leveraging shared technology across multiple product lines. This approach not only accelerates development timelines but also reduces costs [2].
Jeb Besser, CEO of Modular Medical, commented, "This is another step in the maturation of the Modular Medical patch pump delivery platform. The pump controller module for MODD1 and the tubeless Pivot are identical, and the successful delivery of insulin has been a milestone we have anticipated since we began development."
Modular Medical's focus on a user-friendly and affordable design aims to address the limitations of current insulin delivery systems that have prevented wider adoption among patients who could benefit from pump therapy [2].
The company's successful human testing phase represents one of the final steps before potential commercial deployment, though regulatory requirements for expanded use will need to be satisfied before full market release. This methodical approach—starting with a single clinician before expanding—aligns with best practices in medical device development by allowing for controlled assessment before broader deployment [2].
References
[1] https://www.newswire.com/news/modular-medical-announces-modd1-cartridge-line-validated-for-human-use
[2] https://www.stocktitan.net/news/MODD/modular-medical-announces-first-human-use-of-modd1-pump-delivering-y9zn4o8av6vc.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet